Choose KENGREAL® (cangrelor), the Only IV P2Y12 Platelet Inhibitor1

For Confidence During High-Risk or Complex PCI*

Count on KENGREAL for platelet inhibition with a rapid 2-minute onset and 1-hour offset.1

Pharmacology

Consider KENGREAL for high-risk PCI cases

Learn about KENGREAL’s benefit in PCI and its potential to reduce thrombotic events.2,3

Clinical Data

Dosing not impacted by age or renal/hepatic function1

Weight-based dosing for both bolus and infusion administration, can be prepared in the Cath Lab.

Dosing & Administration

Clinical insights into using KENGREAL in PCI

Learn more about KENGREAL’s important role in PCI.

Stopwatch icon

Which cases call for KENGREAL?

Time is of the essence. See patient scenarios that call for KENGREAL, including a STEMI case, an NSTEMI case, and an emergent case in a patient with absorption issues.

See Use Cases
Phone and email support icon

We are here to
support you

Get connected to a rep to learn more about KENGREAL.

Request a Rep
Clinical resources icon

Explore clinical
resources

Learn more about KENGREAL through these go-to resources, including dosing and stocking instructions.

See Resources

IV=intravenous; NSTEMI=non-ST-elevation myocardial infarction; PCI=percutaneous coronary intervention; STEMI=ST-elevation myocardial infarction.

*In a post hoc analysis of CHAMPION PHOENIX, the absolute benefit of KENGREAL increased progressively with the number of high-risk lesion features treated and was greatest for patients with ≥3.2 

View More

Important Safety Information

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

Please see Full Prescribing Information.

Indication

KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

References: 1. KENGREAL® (cangrelor) Prescribing Information. 2022. 2. Stone GW, Généreux P, Harrington RA, et al. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. Eur Heart J. 2018;39(46):4112-4121. 3. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-1313.

Back
to top